Ciro Franzese, Associate Professor in Radiation Oncology at Humanitas University, shared on LinkedIn:
“Joining forces against kidney cancer!
Proud to have contributed to an international multicenter study of stereotactic radiotherapy for renal cell carcinoma.
SBRT is confirmed as a valid therapeutic option with:
- 96% local control at 5 years
- Good preservation of renal function
- acceptable toxicity profile, with only 1% of events grade ≥ 3
A step forward to offer inoperable patients an effective and non-invasive therapeutic option.”
Authors: Ludwige Abancourt, et al.
